WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-inflammatory properties via MKP-1 in LPS-stimulated RAW264.7 macrophages

British Journal of Pharmacology

Volumn 172, Issue 7, 2015, Pages 1894-1908

  Chen, Wei Chuan ^a   Yen, Chia Sheng ^b   Huang, Wei Jan ^a   Hsu, Ya Fen ^c   Ou, George ^d   Hsu, Ming Jen ^a,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c Landseed Hospital   (Taiwan)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CCAAT ENHANCER BINDING PROTEIN; HYDROXAMIC ACID DERIVATIVE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; WMJ S 001; WMJ S 002; WMJ S 003; WMJ S 004; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLOOXYGENASE 2; HYDROXAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NAPHTHALENE DERIVATIVE; NOS2 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; WMJ-S-001;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME REPRESSION; IMMUNOFLUORESCENCE TEST; LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA; LUCIFERASE ASSAY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE; CYCLOOXYGENASE 2; HYDROXAMIC ACIDS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 1; NAPHTHALENES; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 84924907588     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13040     Document Type: Article

References (63)

1. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, et al. (2006). Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203: 1883-1889.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Banks WA, Erickson MA, (2010). The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 37: 26-32.
4. Bertrand S, Helesbeux JJ, Larcher G, Duval O, (2013). Hydroxamate, a key pharmacophore exhibiting a wide range of biological activities. Mini Rev Med Chem 13: 1311-1326.
5. Beutler B, Rietschel ET, (2003). Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3: 169-176.
6. Buck M, Chojkier M, (2007). C/EBPbeta phosphorylation rescues macrophage dysfunction and apoptosis induced by anthrax lethal toxin. Am J Physiol Cell Physiol 293: C1788-C1796.
7. Cao W, Bao C, Padalko E, Lowenstein CJ, (2008). Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med 205: 1491-1503.
8. Chang L, Karin M, (2001). Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
9. Chen L, Fischle W, Verdin E, Greene WC, (2001). Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657.
10. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, et al. (2006). Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A 103: 2274-2279.
11. Chuang YF, Yang HY, Ko TL, Hsu YF, Sheu JR, Ou G, et al. (2014). Valproic acid suppresses lipopolysaccharide-induced cyclooxygenase-2 expression via MKP-1 in murine brain microvascular endothelial cells. Biochem Pharmacol 88: 372-383.
12. Dickinson RJ, Keyse SM, (2006). Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119 (Pt 22): 4607-4615.
13. Dong C, Davis RJ, Flavell RA, (2002). MAP kinases in the immune response. Annu Rev Immunol 20: 55-72.
14. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC, (2005). Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528.
15. Ejima K, Layne MD, Carvajal IM, Kritek PA, Baron RM, Chen YH, et al. (2003). Cyclooxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death. FASEB J 17: 1325-1327.
16. Farooq A, Zhou MM, (2004). Structure and regulation of MAPK phosphatases. Cell Signal 16: 769-779.
17. Frazier WJ, Wang X, Wancket LM, Li XA, Meng X, Nelin LD, et al. (2009). Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice. J Immunol 183: 7411-7419.
18. Gioannini TL, Weiss JP, (2007). Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res 39: 249-260.
19. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, et al. (2006). Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176: 5015-5022.
20. Grant S, Easley C, Kirkpatrick P, (2007). Vorinostat. Nat Rev Drug Discov 6: 21-22.
21. Harper KA, Tyson-Capper AJ, (2008). Complexity of COX-2 gene regulation. Biochem Soc Trans 36 (Pt 3): 543-545.
22. Hotchkiss RS, Karl IE, (2003). The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
23. Hsu MJ, Chang CK, Chen MC, Chen BC, Ma HP, Hong CY, et al. (2010). Apoptosis signal-regulating kinase 1 in peptidoglycan-induced COX-2 expression in macrophages. J Leukoc Biol 87: 1069-1082.
24. Hsu YF, Sheu JR, Lin CH, Chen WC, Hsiao G, Ou G, et al. (2011). MAPK phosphatase-1 contributes to trichostatin A inhibition of cyclooxygenase-2 expression in human umbilical vascular endothelial cells exposed to lipopolysaccharide. Biochim Biophys Acta 1810: 1160-1169.
25. Huang YH, Yang HY, Hsu YF, Chiu PT, Ou G, Hsu MJ, (2013). Src contributes to IL6-induced vascular endothelial growth factor-C expression in lymphatic endothelial cells. Angiogenesis 17: 407-418.
26. Huang YH, Yang HY, Hsu YF, Chiu PT, Ou G, Hsu MJ, (2014). Src contributes to IL6-induced vascular endothelial growth factor-C expression in lymphatic endothelial cells. Angiogenesis 17: 407-418.
27. Jeffrey KL, Camps M, Rommel C, Mackay CR, (2007). Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6: 391-403.
28. Jeong Y, Du R, Zhu X, Yin S, Wang J, Cui H, et al. (2014). Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1. J Leukoc Biol 95: 651-659.
29. Jiang J, Thyagarajan-Sahu A, Krchnak V, Jedinak A, Sandusky GE, Sliva D, (2012). NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS ONE 7: e34283.
30. Jin J, Samuvel DJ, Zhang X, Li Y, Lu Z, Lopes-Virella MF, et al. (2011). Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Mol Immunol 49: 423-432.
31. Kaminska B, (2005). MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754: 253-262.
32. Kang YJ, Wingerd BA, Arakawa T, Smith WL, (2006). Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J Immunol 177: 8111-8122.
33. Kumar S, Boehm J, Lee JC, (2003). p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726.
34. Lang R, Hammer M, Mages J, (2006). DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 177: 7497-7504.
35. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR, (2002). Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22: 7802-7811.
36. Li Q, Verma IM, (2002). NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
37. Lin ML, Lu YC, Chung JG, Wang SG, Lin HT, Kang SE, et al. (2010). Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog 49: 783-797.
38. Liu C, Shi Y, Du Y, Ning X, Liu N, Huang D, et al. (2005). Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Exp Cell Res 309: 410-418.
39. Liu SF, Malik AB, (2006). NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290: L622-L645.
40. Liu Y, Shepherd EG, Nelin LD, (2007). MAPK phosphatases-regulating the immune response. Nat Rev Immunol 7: 202-212.
41. Mbonye UR, Yuan C, Harris CE, Sidhu RS, Song I, Arakawa T, et al. (2008). Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 283: 8611-8623.
42. Medvedev AE, Kopydlowski KM, Vogel SN, (2000). Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol 164: 5564-5574.
43. Monick MM, Robeff PK, Butler NS, Flaherty DM, Carter AB, Peterson MW, et al. (2002). Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J Biol Chem 277: 32992-33000.
44. Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, et al. (1993). Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A 90: 2207-2211.
45. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
46. Raman M, Chen W, Cobb MH, (2007). Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112.
47. Ricciotti E, FitzGerald GA, (2011). Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31: 986-1000.
48. Rodrigues GC, Feijo DF, Bozza MT, Pan P, Vullo D, Parkkila S, et al. (2014). Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. J Med Chem 57: 298-308.
49. Roth RJ, Le AM, Zhang L, Kahn M, Samuel VT, Shulman GI, et al. (2009). MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice. J Clin Invest 119: 3817-3829.
50. Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T, (2006). Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176: 1899-1907.
51. Shishodia S, Koul D, Aggarwal BB, (2004). Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173: 2011-2022.
52. Sweet MJ, Hume DA, (1996). Endotoxin signal transduction in macrophages. J Leukoc Biol 60: 8-26.
53. Tang QQ, Gronborg M, Huang H, Kim JW, Otto TC, Pandey A, et al. (2005). Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis. Proc Natl Acad Sci U S A 102: 9766-9771.
54. Tsoyi K, Jang HJ, Nizamutdinova IT, Kim YM, Lee YS, Kim HJ, et al. (2011). Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 162: 1498-1508.
55. Turpeinen T, Nieminen R, Moilanen E, Korhonen R, (2010). Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells. J Pharmacol Exp Ther 333: 310-318.
56. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, et al. (2013). A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res 19: 4262-4272.
57. Wang Y, Yu C, Pan Y, Li J, Zhang Y, Ye F, et al. (2011). A novel compound C12 inhibits inflammatory cytokine production and protects from inflammatory injury in vivo. PLoS ONE 6: e24377.
58. Williams CS, Mann M, DuBois RN, (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916.
59. Winkler AR, Nocka KN, Williams CM, (2012). Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production. Pulm Pharmacol Ther 25: 286-292.
60. Wu D, Marko M, Claycombe K, Paulson KE, Meydani SN, (2003). Ceramide-induced and age-associated increase in macrophage COX-2 expression is mediated through up-regulation of NF-kappa B activity. J Biol Chem 278: 10983-10992.
61. Wu JJ, Bennett AM, (2005a). Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J Biol Chem 280: 16461-16466.
62. Wu W, Pew T, Zou M, Pang D, Conzen SD, (2005b). Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280: 4117-4124.
63. Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, et al. (2006). MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 203: 131-140.